<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954108</url>
  </required_header>
  <id_info>
    <org_study_id>OTENA-INT-2013-03</org_study_id>
    <secondary_id>CIV-13-07-011543</secondary_id>
    <nct_id>NCT01954108</nct_id>
  </id_info>
  <brief_title>Hyaluronan in the Treatment of Painful Achilles Tendinopathy.</brief_title>
  <official_title>Hyaluronan in the Treatment of Painful Achilles Tendinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare OSTENIL® TENDON (2% hyaluronan) and&#xD;
      Extracorporeal Shock Wave (ESWT) therapy in the treatment of painful Achilles tendinopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Victorian Institute of Sports Assessment-Achilles (VISA-A score)</measure>
    <time_frame>Day 90 (plus or minus 3 days)</time_frame>
    <description>The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Victorian Institute of Sports Assessment-Achilles (VISA-A score)</measure>
    <time_frame>Day 0</time_frame>
    <description>The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Victorian Institute of Sports Assessment-Achilles (VISA-A score)</measure>
    <time_frame>Day 7 (plus or minus 1 day)</time_frame>
    <description>The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Victorian Institute of Sports Assessment-Achilles (VISA-A score)</measure>
    <time_frame>Day 28 (plus or minus 3 days)</time_frame>
    <description>The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Victorian Institute of Sports Assessment-Achilles (VISA-A score)</measure>
    <time_frame>Day 180 (plus or minus 3 days)</time_frame>
    <description>The validated questionnaire will be used to evaluate the outcome in Achilles tendinopathy. The score ranges from '0' to '100' whereas '0' denotes 'no activity / maximum pain' and '100' denote 'maximum activity / no pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm)</measure>
    <time_frame>Day 0</time_frame>
    <description>Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm)</measure>
    <time_frame>Day 7 (plus or minus 1 day)</time_frame>
    <description>Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm)</measure>
    <time_frame>Day 28 (plus or minus 3 days)</time_frame>
    <description>Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm)</measure>
    <time_frame>Day 90 (plus or minus 3 days)</time_frame>
    <description>Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm)</measure>
    <time_frame>Day 180 (plus or minus 3 days)</time_frame>
    <description>Intensity of pain will be evaluated on the Huskisson VAS pain scale on which 0 mm indicate 'no pain' and 100 mm indicate 'extreme pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints</measure>
    <time_frame>Day 7 (plus or minus 1 day)</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints</measure>
    <time_frame>Day 28 (plus or minus 3 days)</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints</measure>
    <time_frame>Day 90 (plus or minus 3 days)</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints</measure>
    <time_frame>Day 180 (plus or minus 3 days)</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameters</measure>
    <time_frame>Day 7 (plus or minus 1 day)</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameters</measure>
    <time_frame>Day 28 (plus or minus 3 days)</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameters</measure>
    <time_frame>Day 90 (plus or minus 3 days)</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameters</measure>
    <time_frame>Day 180 (plus or minus 3 days)</time_frame>
    <description>Redness&#xD;
Warmth&#xD;
Swelling&#xD;
Tenderness on palpation&#xD;
Crepitus on motion&#xD;
Accumulation of tissue fluid&#xD;
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of test product-related Adverse Events</measure>
    <time_frame>Up to Day 180</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>ESWT (Extracorporal Shock Wave Therapy)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three applications in weekly interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyaluronic acid sodium salt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyaluronic acid sodium salt</intervention_name>
    <arm_group_label>hyaluronic acid sodium salt</arm_group_label>
    <other_name>OSTENIL® TENDON</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESWT</intervention_name>
    <arm_group_label>ESWT (Extracorporal Shock Wave Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between 18 and 75 years of age.&#xD;
&#xD;
          -  Good general health condition.&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Painful Achilles midportion tendinopathy since more or equal than 6 weeks.&#xD;
&#xD;
          -  Pain according to VAS (Huskisson, 100 mm) more or equal than 40 mm.&#xD;
&#xD;
          -  Ensured compliance of subjects over the whole study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant or previous participation in a clinical investigation within the last 3&#xD;
             months prior to study inclusion.&#xD;
&#xD;
          -  Infection or relevant skin disease at study relevant site.&#xD;
&#xD;
          -  Blood coagulation disorder or intake of blood thinner (e.g. Marcumar).&#xD;
&#xD;
          -  Known hypersensitivity to hyaluronic acid (HA) preparations or to the constituents&#xD;
             mannitol, sodium chloride, disodium phosphate and sodium dihydrogenphosphate.&#xD;
&#xD;
          -  Contra-indications for ESWT application in study relevant area (e.g. recent surgery,&#xD;
             malignant tumour, local osteomyelitis or open epiphysis).&#xD;
&#xD;
          -  Severe intercurrent illness (e.g. uncontrolled diabetes mellitus, peripheral&#xD;
             neuropathy), which in the opinion of the investigator, may put the patient at risk&#xD;
             when participating in the study, or affect the patient's ability to take part in the&#xD;
             study.&#xD;
&#xD;
          -  Concomitant disease at study relevant site (e.g. insertion tendinopathy at Achilles&#xD;
             tendon) influencing study evaluation.&#xD;
&#xD;
          -  Diseases or characteristics judged by the investigator to be incompatible with the&#xD;
             assessments and/or procedures for the study evaluation.&#xD;
&#xD;
          -  Intake of concomitant medications not allowed which might interfere with the&#xD;
             functional assessment of the study (e.g. immunosuppressive drugs within the last 3&#xD;
             months).&#xD;
&#xD;
          -  Previous therapies (except non-steroidal anti-inflammatory drugs (NSAID)) at study&#xD;
             relevant site within the last 4 weeks prior to study inclusion.&#xD;
&#xD;
          -  Use of NSAIDs within the last week prior to study treatment.&#xD;
&#xD;
          -  Recent history of drug and/or alcohol abuse (within the last 6 months).&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Participants of childbearing age (pre-menopausal) who do not accept the use of methods&#xD;
             of birth control with pearl index of at least 1 (i.e. oral contraceptives, vaginal&#xD;
             ring, hormone-releasing Intrauterine Device (IUD), implants, depot syringes, hormone&#xD;
             patch, double barrier method, tubal ligation, vasectomised partner,…) during the&#xD;
             treatment period and the first 4 weeks of follow-up period.&#xD;
&#xD;
          -  Subjects not capable of contracting and of understanding the nature, risks,&#xD;
             significance and implications of the clinical investigation and unable to form a&#xD;
             rational intention in the light of these facts.&#xD;
&#xD;
          -  Subjects unable to understand informed consent or having a high probability of non&#xD;
             compliance to the study procedures and / or non completion of the study according to&#xD;
             investigator's judgement (e.g. illiteracy, insufficient knowledge of local language).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry De Vroey, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Antwerpen, Fysische Geneeskunde en Revalidatie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils Lynen, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxiszentrum Orthopädie-Unfallchirurgie Nordrhein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen, Fysische Geneeskunde en Revalidatie</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum Orthopädie-Unfallchirurgie Nordrhein</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>September 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2013</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tendinopathy</keyword>
  <keyword>hyaluronan</keyword>
  <keyword>tendon</keyword>
  <keyword>hyaluronic acid</keyword>
  <keyword>extracorporeal shock wave</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

